Search results for " Lymphocyte Count"

showing 2 items of 62 documents

Peripheral Frequency of CD4+ CD28- Cells in Acute Ischemic Stroke: Relationship With Stroke Subtype and Severity Markers.

2015

CD4+ CD28− T cells also called CD28 null cells have been reported as increased in the clinical setting of acute coronary syndrome. Only 2 studies previously analyzed peripheral frequency of CD28 null cells in subjects with acute ischemic stroke but, to our knowledge, peripheral frequency of CD28 null cells in each TOAST subtype of ischemic stroke has never been evaluated. We hypothesized that CD4+ cells and, in particular, the CD28 null cell subset could show a different degree of peripheral percentage in subjects with acute ischemic stroke in relation to clinical subtype and severity of ischemic stroke. The aim of our study was to analyze peripheral frequency of CD28 null cells in subjects…

RiskAcute coronary syndromemedicine.medical_specialtySettore MED/09 - Medicina InternaObservational Study5300Severity of Illness IndexArticleBrain IschemiaBrain ischemiaCD28 AntigensInternal medicineSeverity of illnessmedicineNull cellHumanscardiovascular diseasesStrokeAgedbusiness.industryCase-control studyCD28General MedicineFlow Cytometrymedicine.diseaseLymphocyte Subsetsstroke CD4+ CD28-CD4 Lymphocyte CountPeripheralStrokeCardiovascular DiseasesCase-Control StudiesPhysical therapyCardiologybusiness
researchProduct

Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in children

2010

International audience; We studied lymphocyte recovery in 88 children who consecutively underwent unrelated cord blood transplantation for malignant (n = 64) or nonmalignant (n = 24) diseases. All children but 3 received myeloablative conditioning regimens with pretransplant antithymocyte globulin. Median age was 5.6 years (0.1-18 years) and median follow-up was 40 months (10-136 months). The median dose of infused viable CD45(+) cells (vCD45) was 3.35 × 10(7)/kg with a ratio infused vCD45/collected total nucleated cell at 0.46. Immunologic endpoints were: time to achieve CD3(+) >500 and 1500/mm(3), CD4(+) >500/mm(3), CD8(+) >250/mm(3), CD19(+) >200/mm(3), natural killer >100/mm(3). These e…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyLymphocyteMESH: Antigens CD/analysisCell Count[SDV.GEN] Life Sciences [q-bio]/GeneticsMESH : Child PreschoolGastroenterology0302 clinical medicineMESH : ChildMESH: Child[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyChildChildrenMESH : Lymphocyte Count0303 health sciencesMESH : Cell SurvivalbiologyIncidence (epidemiology)Graft Survival[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematology3. Good healthMESH: Hematologic Diseases/therapy Humansmedicine.anatomical_structureQuartileMESH: Cell SurvivalMESH: Cord Blood Stem Cell Transplantation/methodsLymphocytes recoveryChild PreschoolMESH : Immunophenotyping[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Infant KineticsCord Blood Stem Cell Transplantationmedicine.medical_specialtyMESH: Lymphocyte CountGlobulinMESH: ImmunophenotypingAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyCell SurvivalContext (language use)MESH : Hematologic Diseases/therapy HumansCD19Immunophenotyping03 medical and health sciencesMESH : Lymphocyte Subsets/cytologyAntigens CDInternal medicineMESH : AdolescentmedicineHumansLymphocyte CountMESH : Infant KineticsMESH : Antigens CD45* Cell Count030304 developmental biologyMESH: AdolescentTransplantation[SDV.GEN]Life Sciences [q-bio]/GeneticsUmbilical cord blood transplantationMESH : Graft Survival/immunologybusiness.industryUmbilical Cord Blood TransplantationMESH: Child PreschoolMESH : Cord Blood Stem Cell Transplantation/methodsInfantMESH : Antigens CD/analysisHematologic DiseasesLymphocyte SubsetsSurgeryMESH: Lymphocyte Subsets/cytologyKineticsbiology.proteinMESH: Antigens CD45* Cell CountLeukocyte Common Antigensbusiness[ SDV.GEN ] Life Sciences [q-bio]/GeneticsMESH: Graft Survival/immunologyCD8030215 immunology
researchProduct